Obstetric Emergencies

HELLP Syndrome

IN REVIEWv3🇮🇳 India-firstPENDING CLINICAL VERIFICATION

Haemolysis + Elevated Liver enzymes + Low Platelets — a variant of severe pre-eclampsia that may present WITHOUT marked hypertension. Birth is definitive; transfuse selectively; beware misdiagnosis as gastritis/hepatitis.

Admission & discharge ↓

Reviewer note: Medication regimens and dependent emergency instructions checked 17 October 2026. These targeted checks do not certify every statement in the module. Admission/discharge guidance checked 18 October 2026. This adds a scoped clinical synthesis and does not certify every statement in the module.

Admission & discharge

Care setting: Hospital assessment; severe disease needs admission and possible critical care

Admission/discharge guidance checked 2026-10-18 against the linked sources. This is a clinical checklist for an individual decision, not an automatic discharge order.

When admission or continued hospital care is needed

Admit for severe/persistent hypertension, seizure or neurological symptoms, pulmonary oedema, renal/liver/platelet deterioration, significant pain or fetal compromise.
Eclampsia/HELLP or organ-support needs require appropriate high-dependency/critical-care monitoring, with transfer after initial stabilisation when necessary.

When clinic, day care or home care may be suitable

Antenatal outpatient care is a specialist decision only when maternal/fetal assessment and reliable surveillance support it; recent eclampsia or HELLP is not a routine outpatient pathway.

Before going home

Postnatal NICE transfer criteria: no pre-eclampsia symptoms, BP ≤150/100 mmHg with or without treatment, and blood results stable or improving; all criteria must be met.
Following eclampsia/HELLP, complete indicated seizure prophylaxis/monitoring and document neurological, respiratory, urine-output and blood-test recovery before considering home care. Critical-care step-down and discharge home are separate decisions.
Platelet, haemolysis/liver and renal trends must support recovery; delivery does not immediately resolve every HELLP complication.

Discharge medicines and treatment changes

Continue the selected oral antihypertensive. Stop methyldopa within 2 days after birth; document replacement and review.
The prescriber should consider reduction below 140/90 and reduce below 130/80 mmHg under NICE; provide an individual written adjustment plan. Magnesium loading/infusions are inpatient treatment, not take-home medication.

Medicine doses — use only when indicated

Use the medicines selected for this patient. Listed alternatives are not instructions to prescribe all of them together. Confirm the actual remaining course, pregnancy/postnatal context and monitoring plan.

One selected oral BP option; do not prescribe every alternative together.

Labetalol oralMSFchecked

DoseStart 100 mg twice daily; increase by 100–200 mg increments according to BP; higher daily doses divided three times daily

RouteOral

FrequencyTwice daily initially; three divided doses if higher doses needed

DurationContinue while clinically required; titrate down rather than stop abruptly, with a postpartum review plan

Preparation100 mg or 200 mg tablets; prescribe the strength, dose and administration times

Max dose2400 mg/day

Indication: Maintenance hypertension during pregnancy/postpartum

Monitoring

BP/heart rate, postural symptoms; neonatal glucose/heart-rate observation after late-pregnancy exposure

Contraindications: Asthma, heart block, marked bradycardia, decompensated heart failure

Alternative/adjunct only within the documented BP plan.

Nifedipine extended releaseGovernment of India, MoHFW / NHMchecked

DoseStart sustained-release nifedipine 10 mg twice daily; titrate according to BP and the exact release formulation

RouteOral extended release

FrequencyTwice daily for the cited sustained-release regimen

DurationWhile hypertension persists; reassess after birth and reduce when BP allows

PreparationUse the specified sustained-release tablet, swallowed intact. Other extended-release products may use different strengths/schedules; do not interchange them or use them for acute oral loading.

Max dose80 mg/day for the NHM CEmONC sustained-release regimen

Indication: Maintenance hypertension in pregnancy/postpartum

Monitoring

BP, headache, flushing, oedema and pulse

Contraindications: Maternal hypotension or significant cardiac outflow obstruction

Postpartum only when prescribed, with renal function/potassium monitoring.

Enalapril — postpartum hypertensionMilpharm / emcchecked

DoseStart 5 mg once daily; use a lower supervised initial dose if volume depleted or renally impaired; titrate to BP response

RouteOral

FrequencyOnce daily initially

DurationReview BP and dose after birth; reduce/stop as hypertension resolves or continue for persistent hypertension after medical review

Preparation5 mg tablet swallowed with water, with or without food. Correct volume depletion; check creatinine and potassium before starting

Max dose40 mg/day in the product label; usual maintenance 20 mg/day, not an automatic postpartum target

Indication: After birth only; NICE recommends enalapril with maternal renal-function and potassium monitoring
Renal / hepatic: Renal impairment requires a lower initial dose and adjustment from the product renal table, not the unadjusted 5 mg starter.
NICE NG133 supplies the postpartum choice. Breastfeeding requires extra caution with premature/very young infants; use a suitable alternative when clinically indicated.

Monitoring

BP, symptoms, creatinine/eGFR and potassium before and after initiation/dose changes; infant feeding, alertness and urine output if breastfeeding

Contraindications: Pregnancy, prior ACE-inhibitor angioedema, significant hyperkalaemia; avoid starting in unresolved AKI or severe volume depletion

Tests, pending results and their reviewer

Review platelet count, transaminases and creatinine at 48–72 hours after birth/critical-care step-down; abnormal results need a repeat plan until recovery.
At 6–8 weeks check urine protein; persistent proteinuria (1+ or more) needs a 3-month renal review and referral if kidney function is abnormal.

Home care and counselling

Provide the BP schedule, named reviewer, medicine list and explicit severe-symptom instructions. Discuss recurrence, future-pregnancy planning and long-term cardiovascular risk.

Follow-up: when and what to review

When	Action / responsible service
If on antihypertensives: every 1–2 days for up to 2 weeks after transfer	NICE BP surveillance until off treatment with no hypertension; adapt intensity to findings.
If not on antihypertensives: day 3–5 after birth	Check BP; repeat on alternate days if abnormal.
2 weeks if still on treatment; 6–8 weeks for all	Review medicines, BP, recovery and urine protein; arrange renal follow-up when indicated.

Return urgently

Seizure, severe/persistent headache, visual disturbance, epigastric pain, dyspnoea, chest pain or severe BP: return immediately; postpartum onset can occur after discharge.

Open the complete discharge checklist →

Sources for this plan:

NICE · NG133checked MSFchecked Government of India, MoHFW / NHMchecked Milpharm / emcchecked

Treatment

① Immediate stabilization — first minutes

Admit HDU; IV access; crossmatch
Correct hypovolaemia cautiously (pulmonary oedema risk)
MgSO4 per severe-PE policy
Control BP ≥160/110

③ First-line treatment & drug regimens

STEROIDS if <34+6 wks and birth planned/likely (standard antenatal course; some units extend to 35+6 with caution)
Plan birth: CLASS II HELLP (platelets ≤100) with stable mother ≥34 wks → deliver; <34 wks stable → short expectancy (24–48 h steroids) ONLY in tertiary centre
CLASS I HELLP (platelets ≤50) or any instability → DELIVER regardless of gestation

④ Drug treatment detail (6 agents)

Magnesium sulfate — IV/IM regimenMSFchecked

Dose4 g IV loading, then 5 g deep IM into EACH buttock (10 g IM total); maintenance 5 g IM into alternate buttocks

RouteIV loading + deep IM

FrequencyLoading once; maintenance every 4 hours

DurationContinue until 24 hours after birth OR the last seizure, whichever is later

PreparationUsing 50% (500 mg/mL): 4 g = 8 mL; dilute in 100 mL sodium chloride 0.9% and infuse over 15–20 min. Each 5 g IM dose = 10 mL of 50% solution. Check the actual ampoule strength.

Max doseDo not give maintenance when toxicity criteria are present; do not run an additional magnesium regimen

Indication: Eclampsia: stop seizures and prevent recurrence

Monitoring

Check patellar reflexes, respiratory rate and hourly urine output; monitor BP, pulse and consciousness
Withhold magnesium for absent reflexes, respiratory rate <12/min or urine <100 mL in 4 h; obtain serum magnesium and senior review
Stop magnesium and support ventilation for toxicity; give the calcium-gluconate antidote shown below

Contraindications: Myasthenia gravis, heart block or magnesium toxicity · Renal impairment or oliguria requires reduced/withheld maintenance and more frequent assessment

Magnesium sulfate — IV regimenMSFchecked

Dose4 g IV loading over 15–20 min, then 1 g/hour

RouteIV infusion

FrequencyOne loading dose, then continuous infusion

Duration24 hours after birth or last seizure, whichever is later

Preparation50% solution: withdraw 8 mL (4 g) into 100 mL sodium chloride 0.9% for loading; for maintenance make 20 g up to a FINAL 100 mL (200 mg/mL), run at 5 mL/hour by labelled pump

Max doseUse ONE IV or IV/IM protocol; stop/adjust for toxicity or renal dysfunction

Indication: Eclampsia: alternative when a reliable infusion pump and monitoring are available
Maintenance concentration and pump rate are calculated from the prescribed 1 g/hour; independently check the preparation.

Monitoring

Check patellar reflexes, respiratory rate and hourly urine output; monitor BP, pulse and consciousness
Withhold magnesium for absent reflexes, respiratory rate <12/min or urine <100 mL in 4 h; obtain serum magnesium and senior review
Stop magnesium and support ventilation for toxicity; give the calcium-gluconate antidote shown below

Contraindications: Myasthenia gravis, heart block or magnesium toxicity · Renal impairment or oliguria requires reduced/withheld maintenance and more frequent assessment

Calcium gluconate 10%MSFchecked

Dose1 g (10 mL of 10% solution) slowly

RouteIV

FrequencyInitial antidote dose; reassess breathing, ECG and calcium before further dosing

DurationEmergency reversal; stop magnesium and support the airway concurrently

Preparation10% = 100 mg/mL; 10 mL contains 1 g calcium gluconate, NOT 1 g elemental calcium. Give over at least 5 min through a patent IV line; do not mix with other drugs

Max doseNo automatic repeated-dose course; further calcium requires monitored reassessment

Indication: Antidote for clinically significant magnesium toxicity

Monitoring

Continuous ECG/heart rate; respiratory status, reflexes and injection site; serum calcium/magnesium where available

Contraindications: Extravasation can cause tissue injury; take special care with digoxin · Do not confuse calcium gluconate with calcium chloride

Labetalol IVGovernment of India, MoHFW / NHMchecked

Dose20 mg over 2 min; reassess at 10 min, then 40 mg; further 80 mg doses at 10-min intervals if severe BP persists

RouteIV bolus

Frequency10-minute reassessment and dose sequence

DurationAcute control, then change to an appropriate oral regimen

Preparation5 mg/mL stock: 20 mg = 4 mL, 40 mg = 8 mL, 80 mg = 16 mL. Give each dose slowly, record cumulative dose and check the stock strength

Max dose300 mg cumulative in the cited Indian CEmONC regimen; seek escalation before continuing beyond it

Indication: Persistent severe hypertension in pregnancy or postpartum (systolic ≥160 OR diastolic ≥110 mmHg)

Monitoring

Check BP and pulse before and after each acute dose; fetal monitoring when appropriate
Persistent severe BP despite the initial sequence requires senior/anaesthetic review, a different agent and HDU-level monitoring; avoid uncontrolled stacking

Contraindications: Asthma, bradycardia/heart block or decompensated heart failure

Hydralazine IVMSFchecked

Dose5 mg slowly IV over 2–4 min; reassess for 20 min and repeat 5 mg if still severe

RouteIV

FrequencyEvery 20 min if required after reassessment

DurationAcute control; transition to oral therapy once stable

PreparationReconstitute a 20 mg vial with 1 mL water for injection, then add 9 mL sodium chloride 0.9%: 2 mg/mL. A 5 mg dose = 2.5 mL. Use immediately; do not mix with other drugs

Max dose20 mg cumulative in this MSF bolus regimen

Indication: Alternative for acute severe hypertension
Renal / hepatic: Reduce doses with renal/hepatic impairment

Monitoring

Check BP and pulse before and after each acute dose; fetal monitoring when appropriate
Persistent severe BP despite the initial sequence requires senior/anaesthetic review, a different agent and HDU-level monitoring; avoid uncontrolled stacking

Contraindications: Marked hypotension, severe tachycardia or coronary ischaemia; use cautiously in cardiac disease

Nifedipine immediate releaseGovernment of India, MoHFW / NHMchecked

Dose10 mg swallowed; reassess at 20 min and give another 10–20 mg if still severe

RouteOral, swallowed

FrequencyReassess after each 20-minute interval; switch/escalate when the initial-course limit is reached

DurationAcute sequence, followed by senior review and a separately prescribed maintenance regimen

PreparationUse immediate-release oral tablets/capsules; swallow whole. NEVER sublingual administration; do not use an extended-release tablet as a rapid-loading substitute

Max dose30 mg cumulative for the NHM prose-based initial course; seek senior selection of another agent rather than continuing oral loading

Indication: Acute severe hypertension when oral dosing is appropriate
NHM CEmONC contains an internal discrepancy: its prose caps the initial course at 30 mg, while the adjacent flowchart shows 10 mg then 20 mg then 20 mg. The app uses the 30 mg prose limit with prompt escalation; confirm the locally approved sequence.

Monitoring

Check BP and pulse before and after each acute dose; fetal monitoring when appropriate
Persistent severe BP despite the initial sequence requires senior/anaesthetic review, a different agent and HDU-level monitoring; avoid uncontrolled stacking

Contraindications: Hypotension, significant aortic stenosis or acute cardiac compromise · Magnesium co-administration requires close respiratory/neuromuscular and BP monitoring; follow the named unit protocol

Non-drug treatment

Product	Trigger (typical)	Notes
Platelets	<20×10⁹/L (or <50 with active bleeding/before surgery)	Prophylactic transfusion rarely changes outcome; reserve for bleeding/procedure
PPRC	Symptomatic anaemia/active loss	Restrictive strategy
FFP/cryoprecipitate	Coagulopathy/DIC (fibrinogen <1.5–2 g/L)	Per massive-haemorrhage ratios if bleeding

Definitive treatment

Birth (usually within 24–48 h of onset) — most mothers improve dramatically postpartum; nadir of labs occurs 24–48 h AFTER delivery — expect transient worsening.

Monitoring

Parameter	Frequency
Platelets/LFT/LDH	q8–12h peri-delivery period
Urine output	Hourly in HDU phase
RUQ pain/shoulder tip	Continuous — rupture warning
Fetal CTG	Continuous intrapartum

Treatment failure

Persistent multiorgan failure >72 h postpartum → reconsider diagnosis (TTP/aHUS!) — haematology + plasma exchange
Subcapsular haematoma → IR embolisation/surgery

Procedure / surgery

Regional anaesthesia CONTRAINDICATED if platelets <70–75 or coagulopathy (GA with aspiration precautions)
Caesarean for obstetric indications — not automatic; induction reasonable with Class II stable
Cell-salvage consideration; anticipate PPH

Escalation

ICU: multiorgan dysfunction, ventilatory support, dialysis
Interventional radiology: hepatic artery embolisation for rupture
Haematology: diagnostic uncertainty/plasma exchange

⑮ Complications & their management

DIC

Component therapy per ratio protocol; treat underlying (birth); monitor fibrinogen

Hepatic rupture/infarction

Haemodynamic resuscitation + CT angio + embolisation/laparotomy; massive transfusion activation

AKI

Usually prerenal/AKI of PE — fluid balance, dialysis if indicated

Neonatal thrombocytopenia

Paediatric review at birth (rare serious neonatal disease)

Post-treatment care

Labs normalize over 48–96 h postpartum — verify before discharge
Contraception: avoid COCP until platelets/LFTs normal & BP controlled
Recurrence risk 3–19%; aspirin next pregnancy from 12 wks
Renal/hepatic function recheck at 6 weeks

Diagnosis & assessment

Red flags:

RUQ pain mistaken for "gastritis" in third trimester
Platelets falling fast
Spontaneous bleeding/bruising
Jaundice + dark urine
Fetal compromise

Definition: Microangiopathic haemolysis (schistocytes, LDH >600 IU/L, bilirubin ≥1.2 mg/dL), AST ≥70 IU/L, platelets <100×10⁹/L (Tennessee classification) occurring in pregnancy/peripartum, usually with hypertensive disease.

Initial assessment

Peripheral smear for schistocytes
LDH, indirect bilirubin, haptoglobin
Platelet trend q6–12h
Coagulation incl. fibrinogen (DIC overlap)
Exclude: TTP (ADAMTS13 if available), AFLP (glucose, INR, ammonia), gastroenteritis, hepatitis serology where picture ambiguous

Investigations

Test	Looking for
Smear + retics + LDH	MAHA confirmation
Serial platelets	Rate of fall; nadir typically 24–48 h POSTPARTUM
Glucose + INR	Differentiate acute fatty liver of pregnancy (hypoglycaemia + profound INR rise favour AFLP)
CT/MRI abdomen if RUQ severe	Subcapsular haematoma/hepatic rupture

Principles & follow-up

Management principles

Guideline conflict

India NHM CEmONC, chapter 4 — prose
Acute oral nifedipine: 10 mg, reassess at 20 minutes, repeat 10–20 mg; stated initial-course maximum 30 mg.

Same NHM chapter — adjacent flowchart
The flowchart shows 10 mg, then 20 mg, then another 20 mg at 20-minute reassessments, implying 50 mg.

Population/setting difference: These refer to the same severe-pregnancy-hypertension setting; this is an internal document discrepancy, not a demonstrated population difference.

Practical India consideration: Confirm the sequence formally approved in the treating unit. Extended-release maintenance tablets are a separate regimen.

App default: Use the prose-based 30 mg initial limit with prompt senior reassessment and selection of another agent if severe BP persists.
Reason: This avoids silently combining incompatible limits or prolonging oral loading in uncontrolled severe hypertension.

Guideline conflict

India NHM CEmONC, chapter 4 — prose
20 mg, then 40 mg, then 80 mg at 10-minute reassessments; further dosing may reach a cumulative 300 mg.

Same NHM chapter — adjacent flowchart
Stops the displayed 20 → 40 → 80 mg sequence at a stated 140 mg maximum.

Population/setting difference: Same emergency setting; the flowchart and prose show different stopping points.

Practical India consideration: Use the approved local sequence and track every previous IV dose. Persistent severe BP needs senior/anaesthetic involvement.

App default: The card records the prose ceiling of 300 mg; persistent severe BP after the initial 140 mg sequence requires senior reassessment before additional doses or another agent.
Reason: A cumulative ceiling is not an instruction to continue dosing without reassessing treatment failure and contraindications.

Sources (15)

FOGSI / GESTOSIS-India / ICOG — Hypertensive Disorders in Pregnancy — Good Clinical Practice Recommendations (GCPR), 3rd Edition
2026-01 · checked 2026-08-23 · verified-live
Open source ↗

PDF served from fogsi.org (2026 upload path) — definitions, HDP-Gestosis score, treatment threshold ≥140/90 (WOG), targets ≤140/90, delivery timing (GH term; mild PE 37 wks; severe PE after 34 wks; eclampsia deliver once stabilised post-MgSO4; ≤24 wks immediate delivery better; individualise 24–33+6…

ISSHP — The 2021 ISSHP classification, diagnosis & management recommendations for international practice
2021 (publ 2022 Hypertension) · checked 2026-08-23 · verified-live
Open source ↗

Full PDF: standardised BP measurement; proteinuria PrCr ≥30 mg/mmol, ACR ≥8 mg/mmol or ≥300 mg/day or dipstick 2+ if confirmatory testing unavailable; no 'mild/severe' PE label in ongoing pregnancy; treat all HDP with antihypertensives; severe HTN ≥160/110 treat within minutes-hours monitored; targe…

RCOG — Antenatal Corticosteroids to Reduce Neonatal Morbidity and Mortality (Green-top Guideline No. 74)
2022-02 · checked 2026-08-23 · pending-verification
Open source ↗

Cited via RCOG GTG73 update note; direct PDF audit pending — flag

MSF — Magnesium sulfate: IV/IM and IV regimens
· checked 2026-10-17 · verified-live
Open source ↗

Loading and maintenance doses, 24-hour stopping rule, recurrence ceiling, urine/reflex/respiratory monitoring and toxicity management.

MSF — Calcium gluconate injectable
· checked 2026-10-17 · verified-live
Open source ↗

10% strength, adult initial 1 g IV dose over at least 5 minutes for magnesium toxicity/severe hypocalcaemia; ECG and extravasation precautions.

Government of India, MoHFW / NHM — Revised CEmONC Curriculum 2024, Part 1 — chapter 4
· checked 2026-10-17 · verified-live
Open source ↗

Scanned primary PDF pages 103–104 examined by OCR and visual review: labetalol prose sequence/cumulative 300 mg, sustained-release nifedipine 10 mg twice daily/max 80 mg, and internal prose/flowchart differences for acute nifedipine and labetalol. The app exposes rather than merges the differences.

MSF — Hydralazine injectable
· checked 2026-10-17 · verified-live
Open source ↗

20 mg reconstituted/diluted to 10 mL (2 mg/mL), 5 mg over 2–4 minutes, 20-minute reassessment and cumulative 20 mg bolus regimen.

NICE — NG133 — hypertension in pregnancy
25 June 2019 · updated 17 April 2023 · checked 2026-10-18 · verified-live
Open source ↗

Scope: additional clinical-detail explanation for hdp-postpartum. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Targeted medication audit: Table…

MSF — Labetalol oral
· checked 2026-10-17 · verified-live
Open source ↗

100 mg twice daily with increments, divided higher dosing, 2400 mg/day limit and beta-blocker cautions.

Milpharm / emc — Enalapril 5 mg tablets — SmPC
· checked 2026-10-17 · verified-live
Open source ↗

Hypertension initial 5 mg with volume/renal caution, 40 mg/day maintenance ceiling, creatinine/potassium and pregnancy/feeding warnings. NICE NG133 supplies the separately cited postpartum recommendation.

NICE — Postnatal care — NG194
· checked 2026-10-18 · verified-live
Open source ↗

Maternal/newborn transfer assessment, first void and effective feeding, handover, support/safeguarding, first midwife visit within 36 hours after transfer, postnatal danger symptoms. Full recommendations page read.

India MoHFW / NHM — District Hospital Standard Operating Procedures — LaQshya
· checked 2026-10-18 · verified-live
Open source ↗

Normal-delivery discharge not less than 48 hours: full primary SOP PDF normal-delivery/discharge passages read. Corroborated by NHM CEmONC 2024 Part 1, chapter 8. This does not define a universal post-caesarean or complicated-case stay.

WHO — WHO recommendations on quality postnatal care — official recommendation summary
· checked 2026-10-18 · verified-live
Open source ↗

Official WHO summary read: at least 24-hour facility care after birth; additional contacts at 48–72 hours, 7–14 days and week 6; individual assessment/support. Summary facts only, not a claim that the full 242-page PDF was reviewed.

RCOG — Laparoscopy — recovering well
· checked 2026-10-18 · verified-live
Open source ↗

Full primary patient recovery page read: pain control, wounds, activity/VTE, urinary/bowel and infection warning signs, adult support and no driving/important decisions during the first 24 hours after general anaesthesia. Used as general recovery/handover principles, not operation-specific discharge…

NICE — Acutely ill adults in hospital — CG50
· checked 2026-10-18 · verified-live
Open source ↗

Full primary recommendations read, focusing on critical-care-to-ward transfer: structured written handover, shared plan, monitoring, rehabilitation and receiving-team capability. Step-down is distinct from home discharge; no universal organ-support discharge cutoff is asserted.